[ED patients and their female partners prefer tadalafil].
Phosphodiesterase type 5 (PDE5) inhibitors, sildenafil, tadalafil and vardenafil, are the first-line drugs for the treatment of erectile dysfunction (ED). Giving ED patients the opportunity to try all the three inhibitors can greatly improve the treatment compliance of the patient, whereas the majority of ED patients prefer one specific drug to the others, frequently tadalafil, irrespective of the severity and etiology of the disease, dosing sequence, age of the patient, or dose of medication. Female partners exhibit a similar preference for tadalafil, which has a significant impact on patients' choice. Due to a 36-hour action of tadalafil, patients are allowed to achieve erection within a flexible window of treatment, and not required to schedule the interval between dosing and sexual attempt. The simultaneously decreased time concern will improve the psychological well-being of ED patients and their interpersonal relationship with female partners. Partners who prefer tadalafil feel a return to relaxed and natural sexual activity and the overall improvement in quality of sexual life. The preference of patients and their partners for a specific PDE5 inhibitor should be considered for the purpose of prescription in clinical practice.